Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
In the seventeen month time period of this retrospective study, there were 11,719 HBsAg tests ordered for 9,930 patients (with some patients being tested two or more separate times during the time ...
As outlined in Table 1, the new PCO recommends that when HBV screening is pursued, both HB surface antigen (HBsAg) and HB core antibody (anti-HBc) be tested. 10 It also recommends against screening ...
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group ...
The diagnosis of an active infection by the hepatitis B virus (HBV) relies on testing for the HBV surface antigen (HBsAg). Over the decades the sensitivity of HBsAg assays has increased, and the most ...
Please provide your email address to receive an email when new articles are posted on . Higher end-of-treatment hepatitis B surface antigen level correlated with nucleos(t)ide clinical relapse among ...
The CDC has expanded its testing recommendations for chronic hepatitis B virus (HBV) infection and, for the first time, has provided health professionals with guidance for effective therapy (MMWR.
The results of this study confirm that transient HBsAg positivity can occur in patients who have recent HBV vaccination. In our academic medical center population, we found 11 cases out of 11,719 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback